{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-018595","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2025-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.564016+00:00","generated_at":"2026-05-18T08:47:38.426712+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"MIRA reports SKNY-1 reverses anxiety behavior in animal model, differentiating from older CB1 drugs","bullets":["SKNY-1 reversed anxiety-like behavior in zebrafish induced by a CB1 activator, normalizing to control or better levels.","Prior results showed SKNY-1 achieved up to 30% weight loss, reversed nicotine craving, and preserved muscle mass in animal models.","SKNY-1 is designed to avoid CNS side effects that halted earlier CB1 drugs like rimonabant.","Company is preparing for shareholder approval for acquisition of SKNY Pharmaceuticals; expects to start IND-enabling studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-018595","json":"https://secwatch.observer/filing/0001641172-25-018595.json","markdown":"https://secwatch.observer/filing/0001641172-25-018595.md","text":"https://secwatch.observer/filing/0001641172-25-018595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225018595/0001641172-25-018595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225018595/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:47:38.426712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}